Peculiarities of treatment of patients with comorbid pathology: chronic pancreatitis and hypothyroidism, taking into account SEPP1 gene polymorphism (RS7579)

Authors

DOI:

https://doi.org/10.15587/2519-4798.2023.295472

Keywords:

chronic pancreatitis, hypothyroidism, SEPP1(rs 7579) gene polymorphism, sodium selenite drug

Abstract

Optimization of therapeutic regimens during the treatment of the polymorbid course of chronic pancreatitis combined with hypothyroidism is an important task of modern science.

Aim: to treat patients with comorbid pathology: chronic pancreatitis and hypothyroidism, taking into account the polymorphism of the SEPP1 gene (RS7579)

Materials and methods. During the research, we examined 128 people. Patients were divided into 3 groups. The first group included 48 patients with chronic pancreatitis, the second - 50 patients with chronic pancreatitis in combination with hypothyroidism, and the third - 30 practically healthy people.

Results. Symptoms of maldigestion decreased in 72 % of the examined patients. Signs of nutritional deficiency have significantly decreased, and general well-being has improved. Multicomponent therapy also affected mood, sleep, and reduced irritability and symptoms of depression and anxiety disorders. A multisystemic polysyndromic approach to treatment led to improvements in both pancreatic and thyroid function. The effectiveness of the treatment strategy for patients with chronic pancreatitis was dependent on individual characteristics, such as the severity of chronic pancreatitis, the presence of primary hypothyroidism, the degree of selenium deficiency and concomitant symptoms, taking into account polymorphic variants of the SEPP1 (rs7579) gene. Selenoid deficiency decreased, especially in the group with a combination of chronic pancreatitis and hypothyroidism. The improvement in thyroid hormone activity included a 40.46 % decrease in blood TSH and a 2.5-fold increase in free T4.

Conclusions. The program of complex therapy led to the normalization of the condition of patients with the G-allele genotype of the SEPP1 gene (rs7579), as evidenced by significant improvements in most of the analyzed indicators. The concentration of fecal elastase 1 and blood selenoprotein P significantly increased, and the level of serum pancreatic α-amylase significantly decreased in carriers of the AA genotype. Under the influence of therapy, there were also changes in the hormonal activity of the thyroid gland, a decrease in the concentration of total metabolites of NO, and an improvement in the health indicators of the cardiovascular system. However, for patients with the AA genotype of the SEPP1 (rs7579) gene, continuation of therapy remains important to achieve an optimal condition, in particular, to manage cholesterol levels and other cardiovascular risk factors

Author Biographies

Veronika Ratsa, Bukovinian State Medical University

Assistant

Department of Internal Medicine

Olexandr Fediv, Bukovinian State Medical University

Doctor of Medical Sciences, Professor, Head of Department

Department of Internal Medicine

Larisa Sydorchuk, Bukovinian State Medical University

Doctor of Medical Sciences, Professor, Head of Department

Department of Family Medicine

References

  1. Beyer, G., Habtezion, A., Werner, J., Lerch, M. M., Mayerle, J. (2020). Chronic pancreatitis. The Lancet, 396 (10249), 499–512. doi: https://doi.org/10.1016/s0140-6736(20)31318-0
  2. Löhr, J. M., Dominguez‐Munoz, E., Rosendahl, J., Besselink, M., Mayerle, J., Lerch, M. M. et al. (2017). United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterology Journal, 5 (2), 153–199. doi: https://doi.org/10.1177/2050640616684695
  3. Xu, Y.-W., Li, R., Xu, S.-C. (2020). Hypothyroidism with elevated pancreatic amylase and lipase without clinical symptoms: A case report. World Journal of Clinical Cases, 8 (15), 3299–3304. doi: https://doi.org/10.12998/wjcc.v8.i15.3299
  4. Kyriacou, A., McLaughlin, J., Syed, A. A. (2015). Thyroid disorders and gastrointestinal and liver dysfunction: A state of the art review. European Journal of Internal Medicine, 26 (8), 563–571. doi: https://doi.org/10.1016/j.ejim.2015.07.017
  5. Stuss, M., Michalska-Kasiczak, M., Sewerynek, E. (2017). The role of selenium in thyroid gland pathophysiology. Endokrynologia Polska, 68 (4), 440–465. doi: https://doi.org/10.5603/ep.2017.0051
  6. Kravchenko, V. I., Grossman, A. B., Rakov, O. V., Kovzun, O. I., Pankiv, V. I,, Simurov, O. V. (2021). Selenium supply and thyroid condition in Graves’ disease in the region of iodine deficiency. Problemi Endokrinnoi Patologii, 75 (1), 26–33. doi: https://doi.org/10.21856/j-pep.2021.1.04
  7. Hill, K. E., Zhou, J., McMahan, W. J., Motley, A. K., Atkins, J. F., Gesteland, R. F., Burk, R. F. (2003). Deletion of Selenoprotein P Alters Distribution of Selenium in the Mouse. Journal of Biological Chemistry, 278 (16), 13640–13646. doi: https://doi.org/10.1074/jbc.m300755200
  8. Saito, Y. (2021). Selenium Transport Mechanism via Selenoprotein P – Its Physiological Role and Related Diseases. Frontiers in Nutrition, 8. doi: https://doi.org/10.3389/fnut.2021.685517
  9. Bosschaerts, T., Guilliams, M., Noel, W., Hérin, M., Burk, R. F., Hill, K. E. et al. (2008). Alternatively Activated Myeloid Cells Limit Pathogenicity Associated with African Trypanosomiasis through the IL-10 Inducible Gene Selenoprotein P. The Journal of Immunology, 180 (9), 6168–6175. doi: https://doi.org/10.4049/jimmunol.180.9.6168
  10. Brown, K., Arthur, J. (2001). Selenium, selenoproteins and human health: a review. Public Health Nutrition, 4 (2b), 593–599. doi: https://doi.org/10.1079/phn2001143
  11. Mao, J., Vanderlelie, J. J., Perkins, A. V., Redman, C. W., Ahmadi, K. R., Rayman, M. P. (2016). Genetic polymorphisms that affect selenium status and response to selenium supplementation in United Kingdom pregnant women. The American Journal of Clinical Nutrition, 103 (1), 100–106. doi: https://doi.org/10.3945/ajcn.115.114231
  12. Moriguchi Watanabe, L., Bueno, A. C., de Lima, L. F., Ferraz-Bannitz, R., Dessordi, R., Guimarães, M. P. et al. (2021). Genetically determined variations of selenoprotein P are associated with antioxidant, muscular, and lipid biomarkers in response to Brazil nut consumption by patients using statins. British Journal of Nutrition, 127 (5), 679–686. doi: https://doi.org/10.1017/s000711452100146x
  13. Unifikovanyi klinichnyi protokol pervynnoi ta spetsializovanoi medychnoi dopomohy "Khronichnyi pankreatyt" (2023). MOZ: DP "Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy". Available at: https://www.dec.gov.ua/wp-content/uploads/2023/07/1204_05072023_ukpmd.pdf
  14. Khronichnyi pankreatyt. Klinichna nastanova, zasnovana na dokazakh (2023). MOZ: DP "Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy". Available at: https://www.dec.gov.ua/wp-content/uploads/2023/07/2023_kn_hronichnyj-pankreatyt.pdf
  15. Urgatz, B., Razvi, S. (2023). Subclinical hypothyroidism, outcomes and management guidelines: a narrative review and update of recent literature. Current Medical Research and Opinion, 39 (3), 351–365. doi: https://doi.org/10.1080/03007995.2023.2165811
  16. Durante, C., Hegedüs, L., Czarniecka, A., Paschke, R., Russ, G., Schmitt, F., Soares, P., Solymosi, T., Papini, E. (2023). 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. European Thyroid Journal, 12 (5). doi: https://doi.org/10.1530/etj-23-0067
  17. Vrodzhenyi hipotyreoz. Klinichna nastanova, zasnovana na dokazakh (2023). MOZ: DP "Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy". Available at: https://www.dec.gov.ua/wp-content/uploads/2023/07/2023_kn_vrodzhenyj-gipotyreoz.pdf
  18. Moshtaghi, A., Amini, G., Salehi, R., Kazemi, M., Behjati, M., Khosravi, S. (2019). Evaluation of SEPP1 and Selenoprotein S Gene Polymorphisms (RS7579 and RS34713741) in Relation to Colorectal Cancer Susceptibility in Subset of Iranian Population: A Case-control Study. Advanced Biomedical Research, 8 (1), 47. doi: https://doi.org/10.4103/abr.abr_249_18
  19. Mosallaei, M., Simonian, M., Ahangari, F., Miraghajani, M., Mortazavi, D., Salehi, A. R. et al. (2018). Single nucleotide polymorphism rs4648298 in miRNAs hsa-miR21 and hsa-miR590 binding site of COX gene is a strong colorectal cancer determinant. Journal of Gastrointestinal Oncology, 9 (3), 448–457. doi: https://doi.org/10.21037/jgo.2017.11.01
Peculiarities of treatment of patients with comorbid pathology: chronic pancreatitis and hypothyroidism, taking into account SEPP1 gene polymorphism (RS7579)

Downloads

Published

2023-09-30

How to Cite

Ratsa, V., Fediv, O., & Sydorchuk, L. (2023). Peculiarities of treatment of patients with comorbid pathology: chronic pancreatitis and hypothyroidism, taking into account SEPP1 gene polymorphism (RS7579). ScienceRise: Medical Science, (5(56), 36–41. https://doi.org/10.15587/2519-4798.2023.295472

Issue

Section

Medical Science